Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile

Author:

Boekhoud Ilse M1,Sidorov Igor1,Nooij Sam12,Harmanus Céline1,Bos-Sanders Ingrid M J G1,Viprey Virginie3,Spittal William3,Clark Emma3,Davies Kerrie34,Freeman Jane34,Kuijper Ed J145,Smits Wiep Klaas124ORCID,Bonten Marc,Davies Kerrie A,Kuijper Ed J,Rupnik Maja,Wingen-Heiman Sebastian,Tacconelli Evelina,Wilken Tuba,Petrosillo Nicolla,

Affiliation:

1. Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

2. Center for Microbiome Analyses and Therapeutics, Leiden University Medical Center, Leiden, The Netherlands

3. Healthcare Associated Infection Research Group, School of Medicine, University of Leeds, Leeds, UK

4. European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Study Group for Clostridioides difficile (ESGCD), Basel, Switzerland

5. National Institute for Public Health and the Environment, Bilthoven, The Netherlands

Abstract

Abstract Background Until recently, metronidazole was the first-line treatment for Clostridioides difficile infection and it is still commonly used. Though resistance has been reported due to the plasmid pCD-METRO, this does not explain all cases. Objectives To identify factors that contribute to plasmid-independent metronidazole resistance of C. difficile. Methods Here, we investigate resistance to metronidazole in a collection of clinical isolates of C. difficile using a combination of antimicrobial susceptibility testing on different solid agar media and WGS of selected isolates. Results We find that nearly all isolates demonstrate a haem-dependent increase in the MIC of metronidazole, which in some cases leads to isolates qualifying as resistant (MIC >2 mg/L). Moreover, we find an SNP in the haem-responsive gene hsmA, which defines a metronidazole-resistant lineage of PCR ribotype 010/MLST ST15 isolates that also includes pCD-METRO-containing strains. Conclusions Our data demonstrate that haem is crucial for medium-dependent metronidazole resistance in C. difficile.

Funder

The COMBACTE-CDI

Innovative Medicines Initiative 2 Joint Undertaking

Vidi fellowship

Netherlands Organisation for Scientific Research

Leiden University Medical Center

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3